Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Cardiac Tissue Generated from Human Embryonic Stem Cells Displays Aspects of Both Mature and Immature Heart Muscle

By BiotechDaily International staff writers
Posted on 19 Feb 2014
An in vitro model system based on cardiac tissue generated from human embryonic stem cells displayed some of the physiological responses known to occur in the natural adult human heart while other responses more closely mimicked the immature or newborn human heart.

Cardiac experimental biology and translational research would benefit from an in vitro surrogate for human heart muscle. To this end, investigators at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) studied the structural and functional properties and interventional responses of human engineered cardiac tissues (hECTs) compared to normal human heart tissues.

After transforming human embryonic stem cells into hECTs the investigators mixed them with collagen and cultured them on force-sensing elastomer devices that exercised the tissue and permitted measurement of its contractile force throughout the culture process.

Results published in the February 2014 issue of the FASEB Journal revealed that within seven to 10 days, the induced cardiac cells self-assembled into a three-dimensional strip of tissue that beat spontaneously in a manner similar to natural heart muscle. The cultured strips of tissue, which were able to survive for at least a month, displayed contractile activity in a rhythmic pattern of 70 beats per minute on average.

The heart tissue model responded to electrical and chemical stimulation and was able to incorporate new genetic information delivered by adenovirus gene therapy. During functional analysis, the hECTs displayed some responses known to occur in the natural adult human heart, while other responses more closely mimicked the immature or newborn human heart.

"We hope that our human engineered cardiac tissues will serve as a platform for developing reliable models of the human heart for routine laboratory use," said senior author Dr. Kevin D. Costa, associate professor of cardiology and at the Icahn School of Medicine at Mount Sinai. "This could help accelerate and revolutionize cardiology research by improving the ability to efficiently discover, design, develop, and deliver new therapies for the treatment of heart disease, and by providing more efficient screening tools to identify and prevent cardiac side effects, ultimately leading to safer and more effective treatments for patients suffering from heart disease."

Related Links:

Icahn School of Medicine at Mount Sinai



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.